Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel

Kitsada Wudhikarn; Radhika Bansal; Arushi Khurana; Matthew A. Hathcock; Sherri A. Braksick; N. Nora Bennani; Jonas Paludo; Jose C. Villasboas; Yucai Wang; Patrick B. Johnston; Stephen M. Ansell; Yi Lin

doi:10.1002/ajh.26330

Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel

Kitsada Wudhikarn, Radhika Bansal, Arushi Khurana, Matthew A. Hathcock, Sherri A. Braksick, N. Nora Bennani, Jonas Paludo, Jose C. Villasboas, Yucai Wang, Patrick B. Johnston, Stephen M. Ansell, Yi Lin

Hematology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E427-E430
Journal	American journal of hematology
Volume	96
Issue number	11
DOIs	https://doi.org/10.1002/ajh.26330
State	Published - Nov 1 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26330

Cite this

Wudhikarn, K., Bansal, R., Khurana, A., Hathcock, M. A., Braksick, S. A., Bennani, N. N., Paludo, J., Villasboas, J. C., Wang, Y., Johnston, P. B., Ansell, S. M., & Lin, Y. (2021). Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. American journal of hematology, 96(11), E427-E430. https://doi.org/10.1002/ajh.26330

Wudhikarn, K, Bansal, R, Khurana, A, Hathcock, MA, Braksick, SA, Bennani, NN, Paludo, J, Villasboas, JC, Wang, Y, Johnston, PB , Ansell, SM & Lin, Y 2021, 'Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel', American journal of hematology, vol. 96, no. 11, pp. E427-E430. https://doi.org/10.1002/ajh.26330

@article{ac79f695b01a42d7bd3f38a4cfec9def,

title = "Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel",

author = "Kitsada Wudhikarn and Radhika Bansal and Arushi Khurana and Hathcock, {Matthew A.} and Braksick, {Sherri A.} and Bennani, {N. Nora} and Jonas Paludo and Villasboas, {Jose C.} and Yucai Wang and Johnston, {Patrick B.} and Ansell, {Stephen M.} and Yi Lin",

note = "Funding Information: We thank the patients and their families for their participation in our research study. We appreciate all the hard work, excellent patient care and data collection of the nursing staff, advanced practice providers, the staff at Mayo Clinic Cell Therapy Group at Rochester, MN. K.W. receives partial funding and sabbatical support from the King Chulalongkorn Memorial Hospital Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand. There are no fundings or grants associated with this work. Funding Information: Kitsada Wudhikarn, Arushi Khurana, Radhika Bansal, Matthew A. Hathcock, Sherri A. Braksick, Jonas Paludo, Jose C. Villasboas. and Patrick B. Johnston has no conflict of interest. Yucai Wang receives research funding from Incyte, InnoCare, Novartis, Genentech and serves on the advisory board of Eli Lilly. N. Nora Bennani served on advisory boards for Acrotech, Verastem, and Daiichi Sankyo, Inc. Yi Lin provides consultation service to Kite/Gilead, Celgene/BMS, Juno/BMS, BlueBird Bio, Janssen, Legend BioTech, Gamida Cells, Novartis, Lovance, Takeda, Fosun Kite, reports received research support from Kite/Gilead, Celgene/BMS, BlueBird Bio, Janssen, Legend Biotech, Merck, Takeda and Boston Scientific and served on Drug safety monitoring board of Sorrento. All financial supports and funding are paid to Mayo clinic. Funding Information: We thank the patients and their families for their participation in our research study. We appreciate all the hard work, excellent patient care and data collection of the nursing staff, advanced practice providers, the staff at Mayo Clinic Cell Therapy Group at Rochester, MN. K.W. receives partial funding and sabbatical support from the King Chulalongkorn Memorial Hospital Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand. There are no fundings or grants associated with this work. ",

year = "2021",

month = nov,

day = "1",

doi = "10.1002/ajh.26330",

language = "English (US)",

volume = "96",

pages = "E427--E430",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel

AU - Wudhikarn, Kitsada

AU - Bansal, Radhika

AU - Khurana, Arushi

AU - Hathcock, Matthew A.

AU - Braksick, Sherri A.

AU - Bennani, N. Nora

AU - Paludo, Jonas

AU - Villasboas, Jose C.

AU - Wang, Yucai

AU - Johnston, Patrick B.

AU - Ansell, Stephen M.

AU - Lin, Yi

N1 - Funding Information: We thank the patients and their families for their participation in our research study. We appreciate all the hard work, excellent patient care and data collection of the nursing staff, advanced practice providers, the staff at Mayo Clinic Cell Therapy Group at Rochester, MN. K.W. receives partial funding and sabbatical support from the King Chulalongkorn Memorial Hospital Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand. There are no fundings or grants associated with this work. Funding Information: Kitsada Wudhikarn, Arushi Khurana, Radhika Bansal, Matthew A. Hathcock, Sherri A. Braksick, Jonas Paludo, Jose C. Villasboas. and Patrick B. Johnston has no conflict of interest. Yucai Wang receives research funding from Incyte, InnoCare, Novartis, Genentech and serves on the advisory board of Eli Lilly. N. Nora Bennani served on advisory boards for Acrotech, Verastem, and Daiichi Sankyo, Inc. Yi Lin provides consultation service to Kite/Gilead, Celgene/BMS, Juno/BMS, BlueBird Bio, Janssen, Legend BioTech, Gamida Cells, Novartis, Lovance, Takeda, Fosun Kite, reports received research support from Kite/Gilead, Celgene/BMS, BlueBird Bio, Janssen, Legend Biotech, Merck, Takeda and Boston Scientific and served on Drug safety monitoring board of Sorrento. All financial supports and funding are paid to Mayo clinic. Funding Information: We thank the patients and their families for their participation in our research study. We appreciate all the hard work, excellent patient care and data collection of the nursing staff, advanced practice providers, the staff at Mayo Clinic Cell Therapy Group at Rochester, MN. K.W. receives partial funding and sabbatical support from the King Chulalongkorn Memorial Hospital Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand. There are no fundings or grants associated with this work.

PY - 2021/11/1

Y1 - 2021/11/1

UR - http://www.scopus.com/inward/record.url?scp=85114296950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85114296950&partnerID=8YFLogxK

U2 - 10.1002/ajh.26330

DO - 10.1002/ajh.26330

M3 - Letter

C2 - 34424554

AN - SCOPUS:85114296950

SN - 0361-8609

VL - 96

SP - E427-E430

JO - American journal of hematology

JF - American journal of hematology

IS - 11

ER -

Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this